89zr-mmot0530a
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01832116)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- MesothelinImmunity, passive
MSLN immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 89-Zirconium
Oral
No
Parenteral
No
Topical
No
Also known as
- 89zr-mmot0530a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01832116 | Phase 1 | Mar 1, 2013 | Free University of Amsterdam, Genentech, University of Groningen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Genentech | For profit | 1 | 0 | 1 | 2013 |
| University of Groningen | Academic/Hospital | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1